ReviewExperimental dermatology2022
New treatments and new assessment instruments for Hidradenitis suppurativa.
Review in Experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Patients' Preference Regarding Patient-Reported Outcome Measures for Hidradenitis Suppurativa: A Cross-Sectional Multicenter Study.Dermatology (Basel, Switzerland) · 2026Article
- Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.Dermatology and therapy · 2025Review
- Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Nursing Knowledge and Skills in Hidradenitis Suppurativa: A Multi-Centre Exploratory Study.Nursing reports (Pavia, Italy) · 2025Article
- Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives.Annals of medicine and surgery (2012) · 2024Review
- Longitudinal remote monitoring of hidradenitis suppurativa: a pilot study.The British journal of dermatology · 2024Article
- Requirements for Brazilian Outpatient Centers of Excellence in Hidradenitis Suppurativa: Consensus Co-Creative Study.Clinical, cosmetic and investigational dermatology · 2023Article
- Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.Frontiers in medicine · 2023Review
- External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.Dermatology (Basel, Switzerland) · 2023Article
- New treatments and new assessment instruments for Hidradenitis suppurativa.Experimental dermatology · 2022Review
- Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander?Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator-assessed and patient-reported outcome measures currently used in HS trials, clinical practice and research. In clinical trial settings, the drawbacks of the HiSCR have become apparent; mainly, it is lack of a dynamic measurement of draining tunnels. The newly developed (dichotomous) IHS4 and HASI-R are backed up by adequate validation data and are good contenders to become the new primary outcome measure in HS clinical trials. Patient-reported outcomes, as well as physician reported measures, are being developed by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). For example, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score is a validated measure of HS-specific quality of life and is already being used in many HS trials. Magnitude of pain measurement via a 0-10 numerical rating scale is well-established; however, consensus is still required to ensure consistent administration and interpretation of the instrument. A longitudinal measurement over multiple days rather than at one time point, such as for example the Pain Index could provide increased reliability and reduced recall bias. Ultimately, these newly developed scores and tools can be included in a standardized registry to be used in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.